secwatch.observer — SEC 8-K summary
======================================

Issuer:     PROTHENA CORP PUBLIC LTD CO (PRTA)
CIK:        0001559053
Form:       8-K
Filed at:   2024-02-15T23:59:59+00:00
Accession:  0001559053-24-000003
Event type: earnings
Sentiment:  neutral
Materiality: 0.60
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Prothena Q4 2023 net loss $67.5M; cash $621M; guides 2024 cash burn ~$208-225M
------------------------------------------------------------------------------

- Net loss Q4 $67.5M ($1.26 loss per share) vs net income $6.3M Q4 2022; full year loss $147.0M.
- Total revenue Q4 $0.3M (vs $49.9M Q4 2022); full year $91.4M including $55M BMS milestone.
- Cash, equivalents & restricted cash $621M at Dec 31, 2023; no debt. 2024 cash use guidance $208-225M.
- Phase 1 PRX012 (Alzheimer's) data update expected 2024; partner BMS to advance BMS-986446 to Phase 2 in 1H2024.
- AFFIRM-AL birtamimab topline (Mayo Stage IV AL amyloidosis) expected between 4Q2024-2Q2025.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1559053/000155905324000003/0001559053-24-000003-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1559053/000155905324000003/prta-20240215.htm
  HTML page:      https://secwatch.observer/filing/0001559053-24-000003

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer